Effect of DapagliFLOzin on Quality of Life in Patients with Type 2 Diabetes in a Real Clinical PrActice

Trial Identifier:	D1690C00043
Sponsor:	AstraZeneca
NCTID::	NCT02719132
Start Date:	July 2016
Primary Completion Date:	November 2017
Condition:	Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russia	Moscow, Russia, 117036

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.